Experience in Finland with Haemophilus influenzae type b vaccines

Vaccine

Volumn 9, Issue SUPPL. 1, 1991, Pages

  Eskola, Juhani ^a   Takala, Aino ^a   Käyhty, Helena ^a   Peltola, Heikki ^a   Mäkelä, P Helena ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

conjugate vaccines; efficacy studies; Haemophilus influenzae type b

Indexed keywords

HAEMOPHILUS INFLUENZAE VACCINE; VACCINE;

ANTIBODY BLOOD LEVEL; BACTEREMIA; CONFERENCE PAPER; CONJUGATE; CONTROLLED STUDY; EPIGLOTTITIS; FINLAND; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MENINGITIS; MORBIDITY; PRESCHOOL CHILD; REVACCINATION; VACCINATION;

ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CHILD, PRESCHOOL; FINLAND; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNOGLOBULIN G; INFANT;

EID: 0025903497     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(91)90174-5     Document Type: Article

References (20)

1. Epidemiology of invasive Haemophilus influenzae type b disease among children in Finland before vaccination with Haemophilus influenzae type b conjugate vaccine
2. Risk factors of invasive Haemophilus influenzae type b disease among children in Finland
3. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100 000 vaccinees 3 months to 5 years of age in Finland
4. Prevention of Haemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine
5. Immunogenicity and reactogenicity of four Haemophilus influenzae type b capsular polysaccharide vaccines in Finnish 24-month-old children
6. Antibody levels achieved in infants by course of Haemophilus influenzae type b polysaccharide/diphtheria toxoid conjugate vaccine
7. Immunogenicity in infants of a vaccine composed of Haemophilus influenzae type b capsular polysaccharide mixed with PDT or conjugated to diphtheria toxoid
8. Immunogenicity of Haemophilus influenzae oligosaccharide-protein (HbOC) and polysaccharide-protein (PRP-D) conjugate vaccines at 4, 6 and 14 months of age
9. Isotype concentrations of human antibodies to Haemophilus influenzae type by polysaccharide (Hib) in young adults immunized with the polysaccharide as such or conjugated to a protein (diphtheria toxoid)
10. Human antibody responses to two conjugate vaccines of Haemophilus influenzae type b saccharides and diphtheria toxin
11. Isotype distribution and bactericidal activity of antibodies after immunization with Haemophilus influenzae type b vaccines at 18–24 months of age
12. Simultaneous administration of Haemophilus influenzae type b capsular polysaccharide-diphtheria toxoid conjugate vaccine with routine diphtheria-tetanus pertussis and inactivated poliovirus vaccinations in childhood
13. Reactogenicity and immunogenicity of combined vaccines for bacteraemic diseases caused by Haemophilus influenzae type b, meningococci and pneumococci in 24-month-old children
14. Quantitative and qualitative characterization of antibody response of infants, children and adults to three Haemophilus influenzae type b (Hib) conjugate vaccines
15. Efficacy of Haemophilus influenzae type b polysaccharide diphtheria toxoid conjugate vaccine in infancy
16. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b
17. Protective efficacy of the HbOC and PRP-D Haemophilus influenzae type b conjugate vaccines when given at 4, 6, and 14 to 18 months of age
18. Clinical experience with Haemophilus influenzae type b conjugate vaccines